{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:25Z","timestamp":1787020765378,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":51,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100016168","name":"Ludwig Boltzmann Gesellschaft","doi-asserted-by":"publisher","award":["LBG_KFG_2024_105"],"award-info":[{"award-number":["LBG_KFG_2024_105"]}],"id":[{"id":"10.13039\/501100016168","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking. We developed patient-derived autologous tumor-immune effusion cocultures (PATECs) as an ex vivo platform to functionally evaluate RT-IO regimens within an immunocompetent tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Malignant pleural and peritoneal effusions (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929) from patients with metastatic solid cancers were processed for biobanking and primary tumor culture. Expandable tumor cultures were established in six effusions and recombined with matched autologous immune cells to generate PATEC. PATEC were treated with radiotherapy (RT), innate immune agonists (STING, TLR7\/8), and immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1, and TIGIT) in combinatorial regimens. Tumor cell death, T-cell activation, cytokine secretion, and CD8\u207a T-cell checkpoint expression were assessed using multiparametric flow cytometry and multiplex immunoassays. Contact dependence of cytotoxicity was evaluated by comparing tumor monocultures, direct cocultures, and transwell-separated cocultures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across conditions, regimens combining RT with a stimulator of interferon genes (STING) agonist were the most tumoricidal in PATEC, with marked interpatient variability and Bliss-defined synergy in a subset of effusions (3\/6). STING agonist-mediated cytotoxicity required immune cells and was attenuated by the spatial separation of the tumor and immune compartments, whereas RT alone produced similar cytotoxicity in monocultures and cocultures at 72\u00a0h, suggesting that the observed RT effect in this assay was predominantly tumor-intrinsic. STING-based RT-IO induced early T-cell activation and a type I interferon-rich cytokine milieu, followed by increased expression of multiple inhibitory checkpoints on CD8\u207a T-cells. A composite CD8\u207a checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PATEC enables the functional dissection of RT-IO combinations in a native effusion-derived tumor-immune microenvironment. The additional tumor cell killing conferred by STING-based RT-IO depends on immune cells and direct tumor-immune contact and varies between patient samples. These findings support the use of PATEC as a functional ex vivo system for testing therapeutic combinations in patient-specific settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03707-5","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:33:58Z","timestamp":1776141238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations"],"prefix":"10.1186","volume":"45","author":[{"given":"Rebecca","family":"Zirnbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphni","family":"Ammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Mosleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Theophil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Fabits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Ali Reza","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Laengle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"5","key":"3707_CR1","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3707_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030.","journal-title":"N Engl J Med"},{"issue":"1","key":"3707_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970.","journal-title":"N Engl J Med"},{"issue":"1","key":"3707_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-22-2235","volume":"29","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, et al. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced\/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib study. Clin Cancer Res. 2023;29(1):110\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2235.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3707_CR5","doi-asserted-by":"publisher","first-page":"e001095","DOI":"10.1136\/jitc-2020-001095","volume":"8","author":"L Siu","year":"2020","unstructured":"Siu L, Brody J, Gupta S, Marabelle A, Jimeno A, Munster P, et al. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and\/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020;8(2):e001095. https:\/\/doi.org\/10.1136\/jitc-2020-001095.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3707_CR6","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(22)00226-1.","journal-title":"Lancet Oncol"},{"key":"3707_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7:258. https:\/\/doi.org\/10.1038\/s41392-022-01102-y.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3707_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","volume":"76","author":"JR Baird","year":"2016","unstructured":"Baird JR, Friedman D, Cottam B, Dubensky TW, Kanne DB, Bambina S, et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2016;76(1):50\u201361. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3619.","journal-title":"Cancer Res"},{"issue":"2","key":"3707_CR9","doi-asserted-by":"publisher","first-page":"e000667","DOI":"10.1136\/jitc-2020-000667","volume":"8","author":"V Stary","year":"2020","unstructured":"Stary V, Wolf B, Unterleuthner D, List J, Talic M, L\u00e4ngle J, et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. J Immunother Cancer. 2020;8(2):e000667. https:\/\/doi.org\/10.1136\/jitc-2020-000667.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"3707_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"issue":"13","key":"3707_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"3707_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.semcancer.2022.05.015","volume":"86","author":"B Petricevic","year":"2022","unstructured":"Petricevic B, Kabiljo J, Zirnbauer R, Walczak H, Laengle J, Bergmann M. Neoadjuvant immunotherapy in gastrointestinal cancers \u2013 the new standard of care? Semin Cancer Biol. 2022;86(Pt 2):834\u201350. https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.015.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"3707_CR13","doi-asserted-by":"publisher","first-page":"e70275","DOI":"10.1002\/mco2.70275","volume":"6","author":"R Zirnbauer","year":"2025","unstructured":"Zirnbauer R, Hametner S, Bergler-Klein J, Kuehrer I, Kulu A, Ammon D et al. Incidence and immunopathology of myositis in rectal cancer patients treated with neoadjuvant immune checkpoint inhibitors and chemoradiotherapy: findings from the CHINOREC trial. MedComm (2020). 2025;6(7):e70275. https:\/\/doi.org\/10.1002\/mco2.70275","journal-title":"MedComm (2020)"},{"issue":"8","key":"3707_CR14","doi-asserted-by":"publisher","first-page":"e2527769","DOI":"10.1001\/jamanetworkopen.2025.27769","volume":"8","author":"J Laengle","year":"2025","unstructured":"Laengle J, Kuehrer I, Kulu A, Kabiljo J, Ammon D, Zirnbauer R, et al. Dual immune checkpoint inhibition plus neoadjuvant chemoradiotherapy in rectal cancer: a randomized clinical trial. JAMA Netw Open. 2025;8(8):e2527769. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27769.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"3707_CR15","doi-asserted-by":"publisher","first-page":"e002459","DOI":"10.1136\/jitc-2021-002459","volume":"9","author":"AC Tan","year":"2021","unstructured":"Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, et al. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer. 2021;9(7):e002459. https:\/\/doi.org\/10.1136\/jitc-2021-002459.","journal-title":"J Immunother Cancer"},{"key":"3707_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s12672-023-00758-4","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Kang H, Lyu L, Xiong W, Hu Y. A target map of clinical combination therapies in oncology: an analysis of ClinicalTrials.gov. Discov Oncol. 2023;14:151. https:\/\/doi.org\/10.1007\/s12672-023-00758-4.","journal-title":"Discov Oncol"},{"key":"3707_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-016-0816-x","volume":"14","author":"G Roscilli","year":"2016","unstructured":"Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, et al. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med. 2016;14:61. https:\/\/doi.org\/10.1186\/s12967-016-0816-x.","journal-title":"J Transl Med"},{"key":"3707_CR18","doi-asserted-by":"publisher","first-page":"19910","DOI":"10.1038\/s41598-019-56356-4","volume":"9","author":"SY Kim","year":"2019","unstructured":"Kim SY, Lee JY, Kim DH, Joo HS, Yun MR, Jung D, et al. Patient-derived cells to guide targeted therapy for advanced lung adenocarcinoma. Sci Rep. 2019;9:19910. https:\/\/doi.org\/10.1038\/s41598-019-56356-4.","journal-title":"Sci Rep"},{"key":"3707_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12967-020-02331-x","volume":"18","author":"CG Wu","year":"2020","unstructured":"Wu CG, Chiovaro F, Curioni-Fontecedro A, Casanova R, Soltermann A. In vitro cell culture of patient-derived malignant pleural and peritoneal effusions for personalised drug screening. J Transl Med. 2020;18:163. https:\/\/doi.org\/10.1186\/s12967-020-02331-x.","journal-title":"J Transl Med"},{"key":"3707_CR20","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1038\/s41467-024-52694-8","volume":"15","author":"R Wegmann","year":"2024","unstructured":"Wegmann R, Bankel L, Festl Y, Lau K, Lee S, Arnold F, et al. Molecular and functional landscape of malignant serous effusions for precision oncology. Nat Commun. 2024;15:8544. https:\/\/doi.org\/10.1038\/s41467-024-52694-8.","journal-title":"Nat Commun"},{"key":"3707_CR21","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1038\/s41467-021-27026-9","volume":"12","author":"ZY Huang","year":"2021","unstructured":"Huang ZY, Shao MM, Zhang JC, Yi FS, Du J, Zhou Q, et al. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion. Nat Commun. 2021;12:6690. https:\/\/doi.org\/10.1038\/s41467-021-27026-9.","journal-title":"Nat Commun"},{"key":"3707_CR22","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s13104-018-3953-x","volume":"11","author":"J Chee","year":"2018","unstructured":"Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, et al. Tumour-associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Res Notes. 2018;11:864. https:\/\/doi.org\/10.1186\/s13104-018-3953-x.","journal-title":"BMC Res Notes"},{"issue":"5","key":"3707_CR23","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00262-020-02781-8","volume":"70","author":"MF Wu","year":"2021","unstructured":"Wu MF, Lin CA, Yuan TH, Yeh HY, Su SF, Guo CL, et al. The M1\/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer. Cancer Immunol Immunother. 2021;70(5):1435\u201350. https:\/\/doi.org\/10.1007\/s00262-020-02781-8.","journal-title":"Cancer Immunol Immunother"},{"key":"3707_CR24","doi-asserted-by":"publisher","first-page":"672747","DOI":"10.3389\/fonc.2021.672747","volume":"11","author":"N Principe","year":"2021","unstructured":"Principe N, Kidman J, Lake RA, Lesterhuis WJ, Nowak AK, McDonnell AM, et al. Malignant pleural effusions\u2014a window into local anti-tumor T cell immunity? Front Oncol. 2021;11:672747. https:\/\/doi.org\/10.3389\/fonc.2021.672747.","journal-title":"Front Oncol"},{"issue":"17","key":"3707_CR25","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.3390\/ijms21176178","volume":"21","author":"R Dhupar","year":"2020","unstructured":"Dhupar R, Okusanya OT, Eisenberg SH, Monaco SE, Ruffin AT, Liu D, et al. Characteristics of malignant pleural effusion resident CD8\u207a T cells from a heterogeneous collection of tumors. Int J Mol Sci. 2020;21(17):6178. https:\/\/doi.org\/10.3390\/ijms21176178.","journal-title":"Int J Mol Sci"},{"key":"3707_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12865-023-00590-z","volume":"24","author":"LL Lv","year":"2023","unstructured":"Lv LL, Wang HB, Zhang YX, Zhai JW, Shen Y, Qu QX, et al. CD39 identifies a specific CD8\u207a T cell population in lung adenocarcinoma-related metastatic pleural effusion. BMC Immunol. 2023;24:53. https:\/\/doi.org\/10.1186\/s12865-023-00590-z.","journal-title":"BMC Immunol"},{"key":"3707_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12935-024-03211-w","volume":"24","author":"S Ge","year":"2024","unstructured":"Ge S, Zhao Y, Liang J, He Z, Li K, Zhang G, et al. Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications. Cancer Cell Int. 2024;24:105. https:\/\/doi.org\/10.1186\/s12935-024-03211-w.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"3707_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41416-022-01839-x","volume":"127","author":"G Zhou","year":"2022","unstructured":"Zhou G, Lieshout R, van Tienderen GS, de Ruiter V, van Royen ME, Boor PPC, et al. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. Br J Cancer. 2022;127(4):649\u201360. https:\/\/doi.org\/10.1038\/s41416-022-01839-x.","journal-title":"Br J Cancer"},{"issue":"6","key":"3707_CR29","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174(6):1586\u2013e159812. https:\/\/doi.org\/10.1016\/j.cell.2018.07.009.","journal-title":"Cell"},{"issue":"1","key":"3707_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41596-019-0232-9","volume":"15","author":"CM Cattaneo","year":"2020","unstructured":"Cattaneo CM, Dijkstra KK, Fanchi LF, Kelderman S, Kaing S, van Rooij N, et al. Tumor organoid\u2013T-cell coculture systems. Nat Protoc. 2020;15(1):15\u201339. https:\/\/doi.org\/10.1038\/s41596-019-0232-9.","journal-title":"Nat Protoc"},{"issue":"8","key":"3707_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.it.2020.06.010","volume":"41","author":"K Yuki","year":"2020","unstructured":"Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid models of tumor immunology. Trends Immunol. 2020;41(8):652\u201364. https:\/\/doi.org\/10.1016\/j.it.2020.06.010.","journal-title":"Trends Immunol"},{"key":"3707_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41420-025-02407-x","volume":"11","author":"J Wang","year":"2025","unstructured":"Wang J, Tao X, Zhu J, Dai Z, Du Y, Xie Y, et al. Tumor organoid-immune co-culture models: exploring a new perspective of tumor immunity. Cell Death Discov. 2025;11:195. https:\/\/doi.org\/10.1038\/s41420-025-02407-x.","journal-title":"Cell Death Discov"},{"issue":"8","key":"3707_CR33","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.7150\/thno.71761","volume":"12","author":"Z Ao","year":"2022","unstructured":"Ao Z, Cai H, Wu Z, Hu L, Li X, Kaurich C, et al. Evaluation of cancer immunotherapy using mini-tumor chips. Theranostics. 2022;12(8):3628\u201336. https:\/\/doi.org\/10.7150\/thno.71761.","journal-title":"Theranostics"},{"issue":"8","key":"3707_CR34","doi-asserted-by":"publisher","first-page":"eabc2331","DOI":"10.1126\/sciadv.abc2331","volume":"7","author":"JM Ayuso","year":"2021","unstructured":"Ayuso JM, Rehman S, Virumbrales-Munoz M, McMinn PH, Geiger P, Fitzgerald C, et al. Microfluidic tumor-on-a-chip model to evaluate the role of tumor environmental stress on NK cell exhaustion. Sci Adv. 2021;7(8):eabc2331. https:\/\/doi.org\/10.1126\/sciadv.abc2331.","journal-title":"Sci Adv"},{"issue":"12","key":"3707_CR35","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00262-023-03572-7","volume":"72","author":"M Chernyavska","year":"2023","unstructured":"Chernyavska M, Masoudnia M, Valerius T, Verdurmen WPR. Organ-on-a-chip models for development of cancer immunotherapies. Cancer Immunol Immunother. 2023;72(12):3971\u201383. https:\/\/doi.org\/10.1007\/s00262-023-03572-7.","journal-title":"Cancer Immunol Immunother"},{"key":"3707_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02845-z","author":"H Liu","year":"2025","unstructured":"Liu H, Noguera-Ortega E, Dong X, Lee WD, Chang J, Aydin SA, et al. A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02845-z.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"3707_CR37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.stem.2024.04.018","volume":"31","author":"TI Maulana","year":"2024","unstructured":"Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil FE, et al. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell. 2024;31(7):989\u2013e10029. https:\/\/doi.org\/10.1016\/j.stem.2024.04.018.","journal-title":"Cell Stem Cell"},{"key":"3707_CR38","doi-asserted-by":"publisher","first-page":"104826","DOI":"10.1016\/j.ebiom.2023.104826","volume":"97","author":"R Jagatia","year":"2023","unstructured":"Jagatia R, Doornebal EJ, Rastovic U, Harris N, Feyide M, Lyons AM, et al. Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing. EBioMedicine. 2023;97:104826. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104826.","journal-title":"EBioMedicine"},{"issue":"2","key":"3707_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/gutjnl-2021-325808","volume":"72","author":"KM Sullivan","year":"2023","unstructured":"Sullivan KM, Jiang X, Guha P, Lausted C, Carter JA, Hsu C, et al. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases. Gut. 2023;72(2):325\u201337. https:\/\/doi.org\/10.1136\/gutjnl-2021-325808.","journal-title":"Gut"},{"key":"3707_CR40","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.1038\/s41598-022-10318-5","volume":"12","author":"HY Seo","year":"2022","unstructured":"Seo HY, Kim SC, Roh WL, Shin YK, Kim S, Kim DW, et al. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types. Sci Rep. 2022;12:6345. https:\/\/doi.org\/10.1038\/s41598-022-10318-5.","journal-title":"Sci Rep"},{"issue":"4","key":"3707_CR41","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.4143\/crt.2022.1630","volume":"55","author":"W Choi","year":"2023","unstructured":"Choi W, Kim YH, Woo SM, Yu Y, Lee MR, Lee WJ, et al. Establishment of patient-derived organoids using ascitic or pleural fluid from cancer patients. Cancer Res Treat. 2023;55(4):1077\u201386. https:\/\/doi.org\/10.4143\/crt.2022.1630.","journal-title":"Cancer Res Treat"},{"issue":"11","key":"3707_CR42","doi-asserted-by":"publisher","first-page":"100622","DOI":"10.1016\/j.crmeth.2023.100622","volume":"3","author":"ZE Tano","year":"2023","unstructured":"Tano ZE, Kiesgen S, Chintala NK, Dozier J, Quach HT, Messinger J, et al. Ex vivo pleural effusion cultures to study chimeric antigen receptor T cell cytotoxicity in an immunocompetent environment. Cell Rep Methods. 2023;3(11):100622. https:\/\/doi.org\/10.1016\/j.crmeth.2023.100622.","journal-title":"Cell Rep Methods"},{"issue":"1","key":"3707_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/cancers16010168","volume":"16","author":"CE \u00d6nder","year":"2023","unstructured":"\u00d6nder CE, Moustafa-Oglou M, Schr\u00f6der SM, Hartkopf AD, Koch A, Seitz CM. Precision immunotherapy utilizing adapter CAR-T cells (AdCAR-T) in metastatic breast cancer leads to target specific lysis. Cancers (Basel). 2023;16(1):168. https:\/\/doi.org\/10.3390\/cancers16010168.","journal-title":"Cancers (Basel)"},{"key":"3707_CR44","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41467-023-36310-9","volume":"14","author":"XZ Huang","year":"2023","unstructured":"Huang XZ, Pang MJ, Li JY, Chen HY, Sun JX, Song YX, et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun. 2023;14:822. https:\/\/doi.org\/10.1038\/s41467-023-36310-9.","journal-title":"Nat Commun"},{"issue":"8","key":"3707_CR45","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","volume":"4","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wang X, Cheng X, Liu Z, Yin Y, Li X, et al. Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer. Nat Cancer. 2023;4(8):1138\u201356. https:\/\/doi.org\/10.1038\/s43018-023-00599-8.","journal-title":"Nat Cancer"},{"key":"3707_CR46","doi-asserted-by":"publisher","first-page":"1157697","DOI":"10.3389\/fimmu.2023.1157697","volume":"14","author":"VS Donnenberg","year":"2023","unstructured":"Donnenberg VS, Luketich JD, Sultan I, Lister J, Bartlett DL, Ghosh S, et al. A maladaptive pleural environment suppresses preexisting anti-tumor activity of pleural infiltrating T cells. Front Immunol. 2023;14:1157697. https:\/\/doi.org\/10.3389\/fimmu.2023.1157697.","journal-title":"Front Immunol"},{"issue":"107","key":"3707_CR47","doi-asserted-by":"publisher","first-page":"eadr4795","DOI":"10.1126\/sciimmunol.adr4795","volume":"10","author":"K Slattery","year":"2025","unstructured":"Slattery K, Yao CH, Mylod E, Scanlan J, Scott B, Crowley JP, et al. Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Sci Immunol. 2025;10(107):eadr4795. https:\/\/doi.org\/10.1126\/sciimmunol.adr4795.","journal-title":"Sci Immunol"},{"issue":"4","key":"3707_CR48","doi-asserted-by":"publisher","first-page":"e23638","DOI":"10.4161\/onci.23638","volume":"2","author":"P Vacca","year":"2013","unstructured":"Vacca P, Martini S, Mingari MC, Moretta L. NK cells from malignant pleural effusions are potent antitumor effectors: a clue for adoptive immunotherapy. Oncoimmunology. 2013;2(4):e23638. https:\/\/doi.org\/10.4161\/onci.23638.","journal-title":"Oncoimmunology"},{"issue":"5","key":"3707_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","volume":"9","author":"M Palta","year":"2019","unstructured":"Palta M, Godfrey D, Goodman KA, Hoffe S, Dawson LA, Dessert D, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322\u201332. https:\/\/doi.org\/10.1016\/j.prro.2019.06.016.","journal-title":"Pract Radiat Oncol"},{"issue":"9","key":"3707_CR50","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"WSME Theelen","year":"2019","unstructured":"Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 2019;5(9):1276\u201382. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1478.","journal-title":"JAMA Oncol"},{"issue":"3","key":"3707_CR51","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","volume":"101","author":"R Lazzari","year":"2018","unstructured":"Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiat Oncol Biol Phys. 2018;101(3):650\u201360. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.03.058.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3707_CR52","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.semdp.2017.11.013","volume":"35","author":"T Bochtler","year":"2018","unstructured":"Bochtler T, L\u00f6ffler H, Kr\u00e4mer A. Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol. 2018;35(3):199\u2013206. https:\/\/doi.org\/10.1053\/j.semdp.2017.11.013.","journal-title":"Semin Diagn Pathol"},{"key":"3707_CR53","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","volume":"8","author":"C Vanpouille-Box","year":"2017","unstructured":"Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. https:\/\/doi.org\/10.1038\/ncomms15618.","journal-title":"Nat Commun"},{"issue":"4","key":"3707_CR54","doi-asserted-by":"publisher","first-page":"e002038","DOI":"10.1136\/jitc-2020-002038","volume":"9","author":"S Demaria","year":"2021","unstructured":"Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, et al. Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 2021;9(4):e002038. https:\/\/doi.org\/10.1136\/jitc-2020-002038.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3707_CR55","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843\u201352. https:\/\/doi.org\/10.1016\/j.immuni.2014.10.019.","journal-title":"Immunity"},{"key":"3707_CR56","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu Y, Crowe WN, Wang L, Lu Y, Petty WJ, Habib AA, et al. An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. Nat Commun. 2019;10:5108. https:\/\/doi.org\/10.1038\/s41467-019-13094-5.","journal-title":"Nat Commun"},{"key":"3707_CR57","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41467-023-37328-9","volume":"14","author":"P Zhang","year":"2023","unstructured":"Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, et al. STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun. 2023;14:1610. https:\/\/doi.org\/10.1038\/s41467-023-37328-9.","journal-title":"Nat Commun"},{"key":"3707_CR58","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-025-02366-y","volume":"24","author":"Q Zeng","year":"2025","unstructured":"Zeng Q, Liu M, Wang Z, Zhou R, Ai K. Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy. Mol Cancer. 2025;24:176. https:\/\/doi.org\/10.1186\/s12943-025-02366-y.","journal-title":"Mol Cancer"},{"key":"3707_CR59","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2019.02.119","volume":"300","author":"M Luo","year":"2019","unstructured":"Luo M, Liu Z, Zhang X, Han C, Samandi LZ, Dong C, et al. Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy. J Control Release. 2019;300:154\u201360. https:\/\/doi.org\/10.1016\/j.jconrel.2019.02.119.","journal-title":"J Control Release"},{"issue":"13","key":"3707_CR60","doi-asserted-by":"publisher","first-page":"6120","DOI":"10.7150\/thno.54881","volume":"11","author":"JC Jagodinsky","year":"2021","unstructured":"Jagodinsky JC, Jin WJ, Bates AM, Hernandez R, Grudzinski JJ, Marsh IR, et al. Temporal analysis of type I interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021;11(13):6120\u201337. https:\/\/doi.org\/10.7150\/thno.54881.","journal-title":"Theranostics"},{"issue":"2","key":"3707_CR61","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/cancers17020175","volume":"17","author":"A Drzyzga","year":"2025","unstructured":"Drzyzga A, Czapla J, Matuszczak S, \u0141asut-Szyszka B, Cicho\u0144 T, Pilny E, et al. Differential response to local stimulator of interferon genes agonist administration in tumors with various stimulator of interferon genes statuses. Cancers (Basel). 2025;17(2):175. https:\/\/doi.org\/10.3390\/cancers17020175.","journal-title":"Cancers (Basel)"},{"key":"3707_CR62","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1038\/s41467-021-22572-8","volume":"12","author":"TJ Hayman","year":"2021","unstructured":"Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, et al. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nat Commun. 2021;12:2327. https:\/\/doi.org\/10.1038\/s41467-021-22572-8.","journal-title":"Nat Commun"},{"issue":"3","key":"3707_CR63","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","volume":"25","author":"JB Hines","year":"2023","unstructured":"Hines JB, Kacew AJ, Sweis RF. The development of STING agonists and emerging results as a cancer immunotherapy. Curr Oncol Rep. 2023;25(3):189\u201399. https:\/\/doi.org\/10.1007\/s11912-023-01361-0.","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"3707_CR64","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clin Cancer Res. 2023;29(13):2435\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0118.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3707_CR65","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1158\/1078-0432.CCR-21-1963","volume":"28","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas. Clin Cancer Res. 2022;28(4):677\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1963.","journal-title":"Clin Cancer Res"},{"key":"3707_CR66","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcell.2020.00041","volume":"8","author":"J Sia","year":"2020","unstructured":"Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol. 2020;8:41. https:\/\/doi.org\/10.3389\/fcell.2020.00041.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"3707_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.7150\/thno.101001","volume":"15","author":"A Deng","year":"2025","unstructured":"Deng A, Fan R, Hai Y, Zhuang J, Zhang B, Lu X, et al. A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy. Theranostics. 2025;15(1):277\u201399. https:\/\/doi.org\/10.7150\/thno.101001.","journal-title":"Theranostics"},{"issue":"45","key":"3707_CR68","doi-asserted-by":"publisher","first-page":"eaaz2738","DOI":"10.1126\/sciimmunol.aaz2738","volume":"5","author":"CJ Nicolai","year":"2020","unstructured":"Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, et al. NK cells mediate clearance of CD8\u207a T cell-resistant tumors in response to STING agonist. Sci Immunol. 2020;5(45):eaaz2738. https:\/\/doi.org\/10.1126\/sciimmunol.aaz2738.","journal-title":"Sci Immunol"},{"issue":"28","key":"3707_CR69","doi-asserted-by":"publisher","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","volume":"119","author":"G Berger","year":"2022","unstructured":"Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E, et al. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. 2022;119(28):e2111003119. https:\/\/doi.org\/10.1073\/pnas.2111003119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3707_CR70","doi-asserted-by":"publisher","first-page":"795048","DOI":"10.3389\/fimmu.2021.795048","volume":"12","author":"L Ou","year":"2021","unstructured":"Ou L, Zhang A, Cheng Y, Chen Y. The cGAS-STING pathway: a promising immunotherapy target. Front Immunol. 2021;12:795048. https:\/\/doi.org\/10.3389\/fimmu.2021.795048.","journal-title":"Front Immunol"},{"issue":"2","key":"3707_CR71","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/eji.201242783","volume":"43","author":"P Vacca","year":"2013","unstructured":"Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. Eur J Immunol. 2013;43(2):550\u201361. https:\/\/doi.org\/10.1002\/eji.201242783.","journal-title":"Eur J Immunol"},{"issue":"1","key":"3707_CR72","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/cei.12845","volume":"186","author":"CY Hu","year":"2016","unstructured":"Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, et al. Interleukin-2 reverses CD8\u207a T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clin Exp Immunol. 2016;186(1):106\u201318. https:\/\/doi.org\/10.1111\/cei.12845.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"3707_CR73","doi-asserted-by":"publisher","first-page":"e28518","DOI":"10.4161\/onci.28518","volume":"3","author":"EB Golden","year":"2014","unstructured":"Golden EB, Frances D, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3(4):e28518. https:\/\/doi.org\/10.4161\/onci.28518.","journal-title":"Oncoimmunology"},{"issue":"21","key":"3707_CR74","doi-asserted-by":"publisher","first-page":"7985","DOI":"10.1158\/0008-5472.CAN-04-1525","volume":"64","author":"CT Garnett","year":"2004","unstructured":"Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985\u201394. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1525.","journal-title":"Cancer Res"},{"issue":"4","key":"3707_CR75","doi-asserted-by":"publisher","first-page":"693","DOI":"10.4049\/jimmunol.2100793","volume":"211","author":"MH Lee","year":"2023","unstructured":"Lee MH, Ratanachan D, Wang Z, Hack J, Adbulrahman L, Shamlin NP, et al. Adaptation of the tumor antigen presentation machinery to ionizing radiation. J Immunol. 2023;211(4):693\u2013705. https:\/\/doi.org\/10.4049\/jimmunol.2100793.","journal-title":"J Immunol"},{"issue":"4","key":"3707_CR76","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang LA, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49(4):754\u2013e7634. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.016.","journal-title":"Immunity"},{"key":"3707_CR77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","volume":"24","author":"Q Wang","year":"2025","unstructured":"Wang Q, Yu Y, Zhuang J, Liu R, Sun C. Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment. Mol Cancer. 2025;24:178. https:\/\/doi.org\/10.1186\/s12943-025-02380-0.","journal-title":"Mol Cancer"},{"issue":"19","key":"3707_CR78","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2024026934","volume":"145","author":"A Linder","year":"2025","unstructured":"Linder A, Nixdorf D, Kuhl N, Piseddu I, Xu TT, Holtermann AV, et al. STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. Blood. 2025;145(19):2149\u201360. https:\/\/doi.org\/10.1182\/blood.2024026934.","journal-title":"Blood"},{"issue":"8","key":"3707_CR79","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1158\/2326-6066.CIR-22-0017","volume":"10","author":"EH Knelson","year":"2022","unstructured":"Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, et al. Activation of tumor-cell STING primes NK-cell therapy. Cancer Immunol Res. 2022;10(8):947\u201361. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0017.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3707_CR80","doi-asserted-by":"publisher","first-page":"2054105","DOI":"10.1080\/2162402X.2022.2054105","volume":"11","author":"Y Da","year":"2022","unstructured":"Da Y, Liu Y, Hu Y, Liu W, Ma J, Lu N, et al. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology. 2022;11(1):2054105. https:\/\/doi.org\/10.1080\/2162402X.2022.2054105.","journal-title":"Oncoimmunology"},{"issue":"2","key":"3707_CR81","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41565-021-01032-w","volume":"17","author":"Y Liu","year":"2022","unstructured":"Liu Y, Wang L, Song Q, Ali M, Crowe WN, Kucera GL, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol. 2022;17(2):206\u201316. https:\/\/doi.org\/10.1038\/s41565-021-01032-w.","journal-title":"Nat Nanotechnol"},{"key":"3707_CR82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y, Targeting. LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3707_CR83","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010.","journal-title":"Immunity"},{"key":"3707_CR84","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1038\/s41467-018-06653-9","volume":"9","author":"CA Egelston","year":"2018","unstructured":"Egelston CA, Avalos C, Tu TY, Simons DL, Jimenez G, Jung JY, et al. Human breast tumor-infiltrating CD8\u207a T cells retain polyfunctionality despite PD-1 expression. Nat Commun. 2018;9:4297. https:\/\/doi.org\/10.1038\/s41467-018-06653-9.","journal-title":"Nat Commun"},{"key":"3707_CR85","doi-asserted-by":"publisher","first-page":"105240","DOI":"10.1016\/j.ebiom.2024.105240","volume":"106","author":"J Mietz","year":"2024","unstructured":"Mietz J, Kaulfuss M, Egli L, Opitz L, M\u00fcnz C, Chijioke O. Human effector CD8\u207a T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model. EBioMedicine. 2024;106:105240. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105240.","journal-title":"EBioMedicine"},{"key":"3707_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09754-w","author":"S Ib\u00e1\u00f1ez-Molero","year":"2026","unstructured":"Ib\u00e1\u00f1ez-Molero S, Veldman J, Simon Nieto J, Traets JJH, George A, Hoefakker K, et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples. Nature. 2026. https:\/\/doi.org\/10.1038\/s41586-025-09754-w.","journal-title":"Nature"},{"issue":"12","key":"3707_CR87","doi-asserted-by":"publisher","first-page":"101831","DOI":"10.1016\/j.xcrm.2024.101831","volume":"5","author":"JP Gu\u00e9gan","year":"2024","unstructured":"Gu\u00e9gan JP, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri LJ, Clot E, et al. Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell Rep Med. 2024;5(12):101831. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101831.","journal-title":"Cell Rep Med"},{"issue":"2","key":"3707_CR88","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","volume":"8","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 2018;8(2):196\u2013215. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0833.","journal-title":"Cancer Discov"},{"key":"3707_CR89","doi-asserted-by":"publisher","first-page":"1180997","DOI":"10.3389\/fimmu.2023.1180997","volume":"14","author":"TM Hulen","year":"2023","unstructured":"Hulen TM, Friese C, Kristensen NP, Granh\u00f8j JS, Borch TH, Peeters MJW, et al. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes. Front Immunol. 2023;14:1180997. https:\/\/doi.org\/10.3389\/fimmu.2023.1180997.","journal-title":"Front Immunol"},{"issue":"1","key":"3707_CR90","doi-asserted-by":"publisher","first-page":"2373519","DOI":"10.1080\/2162402X.2024.2373519","volume":"13","author":"I Eguren-Santamar\u00eda","year":"2024","unstructured":"Eguren-Santamar\u00eda I, Rodr\u00edguez I, Herrero-Martin C, Fern\u00e1ndez de Pi\u00e9rola E, Azpilikueta A, S\u00e1nchez-Gregorio S, et al. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism. Oncoimmunology. 2024;13(1):2373519. https:\/\/doi.org\/10.1080\/2162402X.2024.2373519.","journal-title":"Oncoimmunology"},{"issue":"12","key":"3707_CR91","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41568-022-00517-7","volume":"22","author":"DS Thommen","year":"2022","unstructured":"Thommen DS. Tumour avatars to model patients\u2019 responses to immunotherapy. Nat Rev Cancer. 2022;22(12):660. https:\/\/doi.org\/10.1038\/s41568-022-00517-7.","journal-title":"Nat Rev Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03707-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03707-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:35Z","timestamp":1781647115000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03707-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3707"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03707-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8516163\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved human participants and received approval from the Institutional Review Board of the Medical University of Vienna (No. 2042\/2019). The study was conducted in strict accordance with Good Scientific Practice (GSP) guidelines of the Medical University of Vienna and the most recent Declaration of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}